Cargando…
Patients’ compliance with different administration routes for allergen immunotherapy in Germany
BACKGROUND: Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural co...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216042/ https://www.ncbi.nlm.nih.gov/pubmed/25368517 http://dx.doi.org/10.2147/PPA.S70326 |
_version_ | 1782342200141545472 |
---|---|
author | Egert-Schmidt, Anne-Marie Kolbe, Jan-Marcel Mussler, Sabine Thum-Oltmer, Susanne |
author_facet | Egert-Schmidt, Anne-Marie Kolbe, Jan-Marcel Mussler, Sabine Thum-Oltmer, Susanne |
author_sort | Egert-Schmidt, Anne-Marie |
collection | PubMed |
description | BACKGROUND: Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural course of allergic diseases. According to AIT guidelines and summary of product characteristics (SmPCs), the treatment should be carried out for at least 3 years. It is controversially discussed whether subcutaneous or sublingual administration routes cause higher patients’ compliance. METHODS: German sales data for different preparations of the allergen manufacturer Allergopharma GmbH & Co. KG were retrospectively evaluated for 5 consecutive years, based on prescriptions per patient: pollen sublingual immunotherapy (SLIT) and high-dose hypoallergenic (allergoid) or unmodified depot pollen and mite preparations for subcutaneous immunotherapy (SCIT). To identify patients’ compliance, “completed treatment years” were determined. A completed treatment year was defined by the required number of prescribed allergen preparations according to the recommended dosage scheme given in the respective SmPCs. RESULTS: Prescription data of 85,241 patients receiving pollen or mite SCIT and 706 patients receiving pollen SLIT were included in this analysis. Patients’ compliance for at least 3 treatment years with high-dose hypoallergenic pollen SCIT was higher when administered perennially (60%) compared to preseasonally (27%). Prescriptions for at least 3 years were received from 42% of patients with pollen SCIT and from 45% of patients with mite SCIT. Compliance with SLIT was lowest with only 16% of patients receiving prescriptions for at least 3 treatment years. Children and adolescents were more compliant than adults, independent of whether they received SLIT or SCIT. CONCLUSION: In general, patients’ compliance with SCIT using high-dose hypoallergenic or unmodified depot preparations was higher than with pollen SLIT. Perennial application of SCIT seems to increase compliance in comparison to the preseasonal application. Children and adolescents were most compliant, independent of the preparation applied. |
format | Online Article Text |
id | pubmed-4216042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42160422014-11-03 Patients’ compliance with different administration routes for allergen immunotherapy in Germany Egert-Schmidt, Anne-Marie Kolbe, Jan-Marcel Mussler, Sabine Thum-Oltmer, Susanne Patient Prefer Adherence Original Research BACKGROUND: Allergen immunotherapy (AIT) is the practice of administering gradually increasing quantities of an allergen extract to an allergic subject to ameliorate the symptoms associated with the subsequent exposure to the causative allergen. It is the only treatment that may alter the natural course of allergic diseases. According to AIT guidelines and summary of product characteristics (SmPCs), the treatment should be carried out for at least 3 years. It is controversially discussed whether subcutaneous or sublingual administration routes cause higher patients’ compliance. METHODS: German sales data for different preparations of the allergen manufacturer Allergopharma GmbH & Co. KG were retrospectively evaluated for 5 consecutive years, based on prescriptions per patient: pollen sublingual immunotherapy (SLIT) and high-dose hypoallergenic (allergoid) or unmodified depot pollen and mite preparations for subcutaneous immunotherapy (SCIT). To identify patients’ compliance, “completed treatment years” were determined. A completed treatment year was defined by the required number of prescribed allergen preparations according to the recommended dosage scheme given in the respective SmPCs. RESULTS: Prescription data of 85,241 patients receiving pollen or mite SCIT and 706 patients receiving pollen SLIT were included in this analysis. Patients’ compliance for at least 3 treatment years with high-dose hypoallergenic pollen SCIT was higher when administered perennially (60%) compared to preseasonally (27%). Prescriptions for at least 3 years were received from 42% of patients with pollen SCIT and from 45% of patients with mite SCIT. Compliance with SLIT was lowest with only 16% of patients receiving prescriptions for at least 3 treatment years. Children and adolescents were more compliant than adults, independent of whether they received SLIT or SCIT. CONCLUSION: In general, patients’ compliance with SCIT using high-dose hypoallergenic or unmodified depot preparations was higher than with pollen SLIT. Perennial application of SCIT seems to increase compliance in comparison to the preseasonal application. Children and adolescents were most compliant, independent of the preparation applied. Dove Medical Press 2014-10-24 /pmc/articles/PMC4216042/ /pubmed/25368517 http://dx.doi.org/10.2147/PPA.S70326 Text en © 2014 Egert-Schmidt et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Egert-Schmidt, Anne-Marie Kolbe, Jan-Marcel Mussler, Sabine Thum-Oltmer, Susanne Patients’ compliance with different administration routes for allergen immunotherapy in Germany |
title | Patients’ compliance with different administration routes for allergen immunotherapy in Germany |
title_full | Patients’ compliance with different administration routes for allergen immunotherapy in Germany |
title_fullStr | Patients’ compliance with different administration routes for allergen immunotherapy in Germany |
title_full_unstemmed | Patients’ compliance with different administration routes for allergen immunotherapy in Germany |
title_short | Patients’ compliance with different administration routes for allergen immunotherapy in Germany |
title_sort | patients’ compliance with different administration routes for allergen immunotherapy in germany |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216042/ https://www.ncbi.nlm.nih.gov/pubmed/25368517 http://dx.doi.org/10.2147/PPA.S70326 |
work_keys_str_mv | AT egertschmidtannemarie patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany AT kolbejanmarcel patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany AT musslersabine patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany AT thumoltmersusanne patientscompliancewithdifferentadministrationroutesforallergenimmunotherapyingermany |